Outcomes of Rapid Treatment With Sofosbuvir-Velpatasvir in Patients With Hepatitis C Virus who use Injectable Drugs

Madison Heck, MPH, CHES
​
The following article is a part of conference coverage from the IDWeek 2021, being held virtually from September 29 to October 3, 2021. The team at Infectious Disease Advisor will be reporting on the latest news and research conducted by leading experts in the field. Check back for more from the IDWeek 2021.
Among patients with hepatitis C virus (HCV) infection with a history of injectable drug use, those who underwent rapid treatment with a 7-day course of sofosbuvir-velpatasvir achieved significantly increased cure rates compared with those treated with usual care, according to research presented at IDWeek, held virtually from September 29 to October 3, 2021.


 Researchers conducted a study on patients aged 18 to 29 years with HCV who were treatment naïve and had used injectable drugs within the past 30 days. Patients were randomly assigned in a 1:1 fashion to receive either rapid treatment with sofosbuvir-velpatasvir or usual care. In addition to a 7-day course of sofosbuvir-velpatasvir, patients in the rapid treatment group received a same-day medical evaluation, confirmatory and baseline laboratory testing. Patients in the usual care group received same-day HCV confirmation and facilitated referral to a local healthcare provider. The primary endpoint was sustained virologic response at 12 months.

​TO CONTINUE: https://www.infectiousdiseaseadvisor.com/home/meetings/id-week-2021/sofosbuvir-velpatasvir-treatment-in-patients-with-hepatitis-c-who-inject-drugs/